Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Multi-Agent Therapy for High-Risk Rhabdomyosarcoma
NCT00354744Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jul 2006
- Primary completion
- Jan 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rhabdomyosarcoma (RMS), sponsored by Children's Oncology Group. Started Jul 2006; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT00354744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354744.